Compare Organon & Co. Common Stock (OGN) vs Pure Storage (P) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Pure Storage — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Pure Storage trades at $137.75 (market cap $52.31B). The key difference: Pure Storage is far larger — about 14.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Pure Storage pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Pure Storage for 4 Days on average.
| OGN | P | |
|---|---|---|
Market Cap | $3.62B | $52.31B |
Volume | 2,892,999 | 3,373,937 |
Sector | Health | Technology |
52-Week High | $13.81 | $156.97 |
52-Week Low | $5.70 | $56.99 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $11.04B | $51.52B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Everpure (P) trades at $156.97, up 1.07% today, near its 52-week high. The stock shows strong momentum with a bullish technical signal, supported by three consecutive quarterly earnings beats. Revenue grew from $3.17B in 2025 to $4.3B in 2026, with net income more than doubling. Recent news highlights a 147% six-month surge driven by AI-driven growth targets and positive investor sentiment.
Outlook remains optimistic due to robust earnings performance and AI expansion plans, but high valuation multiples (P/E 215) and overbought technical indicators pose risks. Analyst consensus is strongly bullish with a $141.47 price target, though insider selling and competitive pressures warrant caution for new investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Pure Storage
Pure Storage develops enterprise data storage and data management systems, primarily using all-flash technology. Its platform supports cloud, AI, analytics, and mission-critical application workloads.
Read more on P →
